Healthy Ageing Research Centre, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Department of Clinical Biochemistry, Neyshabur University of Medical Sciences, Neyshabur, Iran.
J Recept Signal Transduct Res. 2024 Feb;44(1):1-7. doi: 10.1080/10799893.2024.2325353. Epub 2024 Mar 12.
Breast cancer is a complex malignancy with diverse molecular and cellular subtypes and clinical outcomes. Despite advances in treatment, breast cancer remains a significant health challenge. However, recent advances in cancer immunotherapy have shown promising results in the treatment of breast cancer, particularly the use of inhibitors that target the immune checkpoint PD1/PDL1. Also, the cGAS-STING pathway, an important part of the innate immune response, has been considered as a major potential therapeutic target for breast cancer. In this narrative review, we provide an overview of the cGAS-STING and PD1/PDL-1 pathway in breast cancer, including their role in tumor development, progression, and response to treatment. We also discuss potential future directions for research.
乳腺癌是一种具有多种分子和细胞亚型以及临床结局的复杂恶性肿瘤。尽管在治疗方面取得了进展，但乳腺癌仍然是一个重大的健康挑战。然而，癌症免疫疗法的最新进展在乳腺癌的治疗中显示出了有希望的结果，特别是使用针对免疫检查点 PD1/PDL1 的抑制剂。此外，cGAS-STING 途径作为先天免疫反应的重要组成部分，已被认为是乳腺癌的一个主要潜在治疗靶点。在这篇叙述性综述中，我们提供了乳腺癌中 cGAS-STING 和 PD1/PDL-1 途径的概述，包括它们在肿瘤发生、发展和对治疗的反应中的作用。我们还讨论了潜在的未来研究方向。
